13-108727495-A-G
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001198950.3(MYO16):āc.419A>Gā(p.Asn140Ser) variant causes a missense change. The variant allele was found at a frequency of 0.000088 in 1,614,032 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.00047 ( 0 hom., cov: 32)
Exomes š: 0.000048 ( 0 hom. )
Consequence
MYO16
NM_001198950.3 missense
NM_001198950.3 missense
Scores
3
15
Clinical Significance
Conservation
PhyloP100: 5.08
Genes affected
MYO16 (HGNC:29822): (myosin XVI) This gene encodes an unconventional myosin protein. The encoded protein has been proposed to act as a serine/threonine phosphatase-1 targeting or regulatory subunit. Studies in a rat cell line suggest that this protein may regulate cell cycle progression. A variant within this gene may be associated with susceptibility to schizophrenia and elevated expression of this gene has been observed in the frontal cortex of human schizophrenia patients. [provided by RefSeq, Mar 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.022643507).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYO16 | NM_001198950.3 | c.419A>G | p.Asn140Ser | missense_variant | 4/35 | ENST00000457511.7 | NP_001185879.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYO16 | ENST00000457511.7 | c.419A>G | p.Asn140Ser | missense_variant | 4/35 | 1 | NM_001198950.3 | ENSP00000401633.3 | ||
MYO16 | ENST00000356711.7 | c.353A>G | p.Asn118Ser | missense_variant | 4/35 | 1 | ENSP00000349145.2 | |||
MYO16 | ENST00000251041.10 | c.353A>G | p.Asn118Ser | missense_variant | 4/25 | 5 | ENSP00000251041.5 |
Frequencies
GnomAD3 genomes AF: 0.000473 AC: 72AN: 152150Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
72
AN:
152150
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000147 AC: 37AN: 251268Hom.: 0 AF XY: 0.000110 AC XY: 15AN XY: 135790
GnomAD3 exomes
AF:
AC:
37
AN:
251268
Hom.:
AF XY:
AC XY:
15
AN XY:
135790
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000479 AC: 70AN: 1461764Hom.: 0 Cov.: 31 AF XY: 0.0000385 AC XY: 28AN XY: 727196
GnomAD4 exome
AF:
AC:
70
AN:
1461764
Hom.:
Cov.:
31
AF XY:
AC XY:
28
AN XY:
727196
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000473 AC: 72AN: 152268Hom.: 0 Cov.: 32 AF XY: 0.000457 AC XY: 34AN XY: 74438
GnomAD4 genome
AF:
AC:
72
AN:
152268
Hom.:
Cov.:
32
AF XY:
AC XY:
34
AN XY:
74438
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
13
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
20
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 13, 2023 | The c.419A>G (p.N140S) alteration is located in exon 4 (coding exon 4) of the MYO16 gene. This alteration results from a A to G substitution at nucleotide position 419, causing the asparagine (N) at amino acid position 140 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;T;.;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
M_CAP
Benign
D
MetaRNN
Benign
T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
L;.;L;L
PrimateAI
Benign
T
PROVEAN
Benign
N;.;N;N
REVEL
Benign
Sift
Benign
T;.;T;T
Sift4G
Uncertain
D;D;D;D
Polyphen
P;.;.;P
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at